[1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. doi:10.3322/caac.21590.
[2] Sanderson P A, Critchley H O, Williams A R, et al. New concepts for an old problem: the diagnosis of endometrial hyperplasia[J]. Hum Reprod Update, 2017, 23(2): 232-254. doi:10.1093/humupd/dmw042.
[3] Eckel R H, Grundy S M, Zimmet P Z. The metabolic syndrome[J]. Lancet, 2005, 365(9468): 1415-28. doi:10.1016/s0140-6736(05)66378-7.
[4] Shou H, Yan K, Song J, et al. Metabolic syndrome affects the long-term survival of patients with non-endometrioid carcinoma of the uterine corpus[J]. Int J Gynaecol Obstet, 2020, 148(1): 96-101. doi:10.1002/ijgo.12984.
[5] The Use of Hysteroscopy for the Diagnosis and Treatment of Intrauterine Pathology: ACOG Committee Opinion, Number 800[J]. Obstet Gynecol, 2020, 135(3): e138-e148. doi:10.1097/aog.0000000000003712.
[6] Yen C F, Chou H H, Wu H M, et al. Effectiveness and appropriateness in the application of office hysteroscopy[J]. J Formos Med Assoc, 2019, 118(11): 1480-1487. doi:10.1016/j.jfma.2018.12.012.
[7] Morice P, Leary A, Creutzberg C, et al. Endometrial cancer[J]. Lancet, 2016, 387(10023): 1094-1108. doi:10.1016/s0140-6736(15)00130-0.
[8] Raffone A, Travaglino A, Saccone G, et al. Diabetes Mellitus Is Associated with Occult Cancer in Endometrial Hyperplasia[J]. Pathol Oncol Res, 2020, 26(3): 1377-1384. doi:10.1007/s12253-019-00684-3.
[9] Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis[J]. Diabetes Care, 2012, 35(11): 2402-11. doi:10.2337/dc12-0336.
[10] Kitson S J, Lindsay J, Sivalingam V N, et al. The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study[J]. Gynecol Oncol, 2018, 148(1): 154-160. doi:10.1016/j.ygyno.2017.11.019.
[11] Arthur R S, Kabat G C, Kim M Y, et al. Metabolic syndrome and risk of endometrial cancer in postmenopausal women: a prospective study[J]. Cancer Causes Control, 2019, 30(4): 355-363. doi:10.1007/s10552-019-01139-5.
[12] Deng T, Lyon C J, Bergin S, et al. Obesity, Inflammation, and Cancer[J]. Annu Rev Pathol, 2016, 11: 421-49. doi:10.1146/annurev-pathol-012615-044359.
[13] Secord A A, Hasselblad V, Von Gruenigen V E, et al. Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis[J]. Gynecol Oncol, 2016, 140(1): 184-90. doi:10.1016/j.ygyno.2015.10.020.
[14] Sung H, Siegel R L, Torre L A, et al. Global patterns in excess body weight and the associated cancer burden[J]. CA Cancer J Clin, 2019, 69(2): 88-112. doi:10.3322/caac.21499.
[15] Roque D R, Makowski L, Chen T H, et al. Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project[J]. Gynecol Oncol, 2016, 142(2): 317-22. doi:10.1016/j.ygyno.2016.06.006.
[16] Ward K K, Roncancio A M, Shah N R, et al. Bariatric surgery decreases the risk of uterine malignancy[J]. Gynecol Oncol, 2014, 133(1): 63-6. doi:10.1016/j.ygyno.2013.11.012.
[17] Lai Y, Sun C. Association of abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer[J]. Oncol Lett, 2018, 15(2): 2173-2178. doi:10.3892/ol.2017.7590.
[18] Mu N, Zhu Y, Wang Y, et al. Insulin resistance: a significant risk factor of endometrial cancer[J]. Gynecol Oncol, 2012, 125(3): 751-7. doi:10.1016/j.ygyno.2012.03.032.
[19] Gu C J, Xie F, Zhang B, et al. High Glucose Promotes Epithelial-Mesenchymal Transition of Uterus Endometrial Cancer Cells by Increasing ER/GLUT4-Mediated VEGF Secretion[J]. Cell Physiol Biochem, 2018, 50(2): 706-720. doi:10.1159/000494237.
[20] Wallbillich J J, Josyula S, Saini U, et al. High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer[J]. PLoS One, 2017, 12(1): e0170318. doi:10.1371/journal.pone.0170318.
[21] Friberg E, Orsini N, Mantzoros C S, et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis[J]. Diabetologia, 2007, 50(7): 1365-74. doi:10.1007/s00125-007-0681-5.
[22] Yang X, Wang J. The Role of Metabolic Syndrome in Endometrial Cancer: A Review[J]. Front Oncol, 2019, 9: 744. doi:10.3389/fonc.2019.00744.
[23] Madak-Erdogan Z, Band S, Zhao Y C, et al. Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling[J]. Cancer Res, 2019, 79(10): 2494-2510. doi:10.1158/0008-5472.Can-18-2849.
[24] Schmandt R E, Iglesias D A, Co N N, et al. Understanding obesity and endometrial cancer risk: opportunities for prevention[J]. Am J Obstet Gynecol, 2011, 205(6): 518-25. doi:10.1016/j.ajog.2011.05.042.
[25] Gibson D A, Collins F, Cousins F L, et al. The impact of 27-hydroxycholesterol on endometrial cancer proliferation[J]. Endocr Relat Cancer, 2018, 25(4): 381-391. doi:10.1530/erc-17-0449.
[26] Aune D, Sen A, Vatten L J. Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case-control and cohort studies[J]. Sci Rep, 2017, 7: 44808. doi:10.1038/srep44808.
[27] Bjørge T, Stocks T, Lukanova A, et al. Metabolic syndrome and endometrial carcinoma[J]. Am J Epidemiol, 2010, 171(8): 892-902. doi:10.1093/aje/kwq006.
[28] Dovell F, Boffetta P. Serum uric acid and cancer mortality and incidence: a systematic review and meta-analysis[J]. Eur J Cancer Prev, 2018, 27(4): 399-405. doi:10.1097/cej.0000000000000440.
[29] Yang J, Wang Y, Zhao Q, et al. Association of serum uric acid with increased risk of cancer among hypertensive Chinese[J]. Int J Cancer, 2017, 141(1): 112-120. doi:10.1002/ijc.30731.
[30] Kühn T, Sookthai D, Graf M E, et al. Albumin, bilirubin, uric acid and cancer risk: results from a prospective population-based study[J]. Br J Cancer, 2017, 117(10): 1572-1579. doi:10.1038/bjc.2017.313.
[31] Yiu A, Van Hemelrijck M, Garmo H, et al. Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study[J]. Oncotarget, 2017, 8(26): 42332-42342. doi:10.18632/oncotarget.16198.
[32] Deberardinis R J. Tumor Microenvironment, Metabolism, and Immunotherapy[J]. N Engl J Med, 2020, 382(9): 869-871. doi:10.1056/NEJMcibr1914890.
[33] Iyengar N M, Gucalp A, Dannenberg A J, et al. Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation[J]. J Clin Oncol, 2016, 34(35): 4270-4276. doi:10.1200/jco.2016.67.4283.
[34] Hutt S, Tailor A, Ellis P, et al. The role of biomarkers in endometrial cancer and hyperplasia: a literature review[J]. Acta Oncol, 2019, 58(3): 342-352. doi:10.1080/0284186x.2018.1540886.